30.05.2022 • News

Azelis Acquires Indian Firms

Azelis has agreed to buy Chemo India and Unipharm Laboratories, distributors of specialty chemicals and ingredients for the coatings, adhesives, sealants & elastomers (CASE), lubricants & metalworking fluids and pharmaceutical market segments in India.

Both companies are headquartered in Mumbai and together add four sites in Bhiwandi, a city in the Thane district of Maharashtra. The transaction is expected to close in the second quarter of 2022. Financial terms were not revealed.

“This acquisition is a sound strategic decision that increases the exceptional assets we already have in the Indian industrial chemicals and pharma markets,” said Laurent Nataf, CEO & president of Azelis Asia-Pacific. “We anticipate many synergies will arise, allowing us to establish an attractive combined comprehensive offering that enables us to provide even more innovative solutions and formulation services, enhancing our value proposition to customers and principals.”

Dhirajilal Shah, founder and co-owner of Chemo India and Unipharm Laboratories, added: “Joining forces with Azelis is beneficial for our company’s evolution, allowing us to further operationalize our resources and develop efficiencies to bring the best of our expertise to the market.”

Author: Elaine Burridge, Freelance Journalist

(c) Azelis
(c) Azelis

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read